Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors
INTRODUCTION: Patients with synchronous (de novo) metastatic castration-sensitive prostate cancer appear to have worse survival outcomes and shorter time to develop castration resistance than patients with metachronous disease. However, the impact of synchronous metastasis on outcomes in metastatic castration-resistant prostate cancer (mCRPC) setting is unknown in patients without prior exposure to androgen receptor pathway inhibitors (ARPIs). In this study, we assessed the impact of initial timing of metastasis (synchronous vs metachronous) on survival outcomes of patients with new-onset mCRPC in a real-world population treated with first-line abiraterone or enzalutamide.
METHODS: Data were collected retrospectively from 323 patients with a confirmed diagnosis of mCRPC who received ARPIs as first-line therapy and had no prior exposure to ARPIs. The study endpoints were progression-free survival and overall survival.
RESULTS: The results showed that median overall survival was significantly shorter in patients with synchronous disease than those with metachronous disease (26 vs 38.7 months, HR 1.42, 95% CI 1.09-1.86, P = .011). However, there was no difference in median progression-free survival.
CONCLUSIONS: The initial presentation with synchronous metastasis remained an independent factor associated with shorter OS in the multivariable analysis. These hypothesis-generating data, after external validation, may have implications in patient counseling, prognostication, and design of future clinical trials in the new-onset mCRPC setting.
| Errataetall: |
CommentIn: Urol Pract. 2024 Jan;11(1):35-36. - PMID 37903751 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Urology practice - 11(2024), 1 vom: 29. Jan., Seite 32-35 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gebrael, Georges [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Androgen Receptor Antagonists |
|---|
| Anmerkungen: |
Date Completed 06.01.2024 Date Revised 12.04.2024 published: Print-Electronic CommentIn: Urol Pract. 2024 Jan;11(1):35-36. - PMID 37903751 Citation Status MEDLINE |
|---|
| doi: |
10.1097/UPJ.0000000000000471 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363957219 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363957219 | ||
| 003 | DE-627 | ||
| 005 | 20240412232544.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/UPJ.0000000000000471 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM363957219 | ||
| 035 | |a (NLM)37903742 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gebrael, Georges |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Pathway Inhibitors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.01.2024 | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Urol Pract. 2024 Jan;11(1):35-36. - PMID 37903751 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Patients with synchronous (de novo) metastatic castration-sensitive prostate cancer appear to have worse survival outcomes and shorter time to develop castration resistance than patients with metachronous disease. However, the impact of synchronous metastasis on outcomes in metastatic castration-resistant prostate cancer (mCRPC) setting is unknown in patients without prior exposure to androgen receptor pathway inhibitors (ARPIs). In this study, we assessed the impact of initial timing of metastasis (synchronous vs metachronous) on survival outcomes of patients with new-onset mCRPC in a real-world population treated with first-line abiraterone or enzalutamide | ||
| 520 | |a METHODS: Data were collected retrospectively from 323 patients with a confirmed diagnosis of mCRPC who received ARPIs as first-line therapy and had no prior exposure to ARPIs. The study endpoints were progression-free survival and overall survival | ||
| 520 | |a RESULTS: The results showed that median overall survival was significantly shorter in patients with synchronous disease than those with metachronous disease (26 vs 38.7 months, HR 1.42, 95% CI 1.09-1.86, P = .011). However, there was no difference in median progression-free survival | ||
| 520 | |a CONCLUSIONS: The initial presentation with synchronous metastasis remained an independent factor associated with shorter OS in the multivariable analysis. These hypothesis-generating data, after external validation, may have implications in patient counseling, prognostication, and design of future clinical trials in the new-onset mCRPC setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a de novo | |
| 650 | 4 | |a mCRPC | |
| 650 | 4 | |a metastatic prostate cancer | |
| 650 | 4 | |a survival | |
| 650 | 4 | |a synchronous disease | |
| 650 | 7 | |a Androgen Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Receptors, Androgen |2 NLM | |
| 700 | 1 | |a Sayegh, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Tripathi, Nishita |e verfasserin |4 aut | |
| 700 | 1 | |a Goel, Divyam |e verfasserin |4 aut | |
| 700 | 1 | |a McFarland, Taylor |e verfasserin |4 aut | |
| 700 | 1 | |a Ebrahimi, Hedyeh |e verfasserin |4 aut | |
| 700 | 1 | |a Nordblad, Blake |e verfasserin |4 aut | |
| 700 | 1 | |a Chigarira, Beverly |e verfasserin |4 aut | |
| 700 | 1 | |a Mathew Thomas, Vinay |e verfasserin |4 aut | |
| 700 | 1 | |a Sahu, Kamal Kant |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Haoran |e verfasserin |4 aut | |
| 700 | 1 | |a Chehrazi-Raffle, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Kohli, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Neeraj |e verfasserin |4 aut | |
| 700 | 1 | |a Swami, Umang |e verfasserin |4 aut | |
| 700 | 1 | |a Maughan, Benjamin L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Urology practice |d 2014 |g 11(2024), 1 vom: 29. Jan., Seite 32-35 |w (DE-627)NLM244581320 |x 2352-0787 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:1 |g day:29 |g month:01 |g pages:32-35 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/UPJ.0000000000000471 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 1 |b 29 |c 01 |h 32-35 | ||